繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Eterna Therapeutics报告第三季度业绩

2025-11-10 22:12

  • Eterna Therapeutics press release (ERNA): Q3  Operating loss decreased $0.3 million, or 12%, from $2.3 million during the three months ended September 30, 2024 to $2.0 million during the three months ended September 30, 2025.
  • General and administrative expenses decreased $2.4 million, or 72%, from $3.4 million during the three-month period ended September 30, 2024 to $1.0 million during the three-month period ended September 30, 2025

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。